GlassScriptPhysician profile
Sam M Nourani
NPI 1528039732
$3,336.08
in general payments reported to CMS, 2019-2025
24 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $773 · 2021: $780 · 2022: $749 · 2023: $267 · 2024: $401 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,022.49 | 2019-2025 | |
| Capsopro Services LLC | $500.00 | 2020 | |
| Celgene Corporation | $381.21 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.87 | 2020-2024 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $196.03 | 2021-2024 | Tremfya |
| Steris Corporation | $168.27 | 2024 | |
| Pfizer INC. | $112.94 | 2019-2025 | |
| Cook Medical LLC | $105.74 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.07 | 2020-2022 | |
| Gilead Sciences, INC. | $80.60 | 2022-2023 | |
| Allergan, INC. | $67.66 | 2019 | |
| Genzyme Corporation | $55.78 | 2023 | |
| Nestle Healthcare Nutrition INC. | $49.64 | 2021-2023 | |
| Qol Medical, LLC | $44.16 | 2022-2024 | Sucraid |
| Lilly USA, LLC | $26.33 | 2024 | Omvoh |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $25.21 | 2024 | Voquezna |
| Ardelyx, INC. | $24.65 | 2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $23.79 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $23.60 | 2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $23.28 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $22.75 | 2022 | |
| Merck Sharp & Dohme LLC | $20.61 | 2021 | |
| Intercept Pharmaceuticals, INC. | $19.21 | 2022 | |
| Daiichi Sankyo INC. | $19.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Nourani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.